Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Pre-diagnostic body mass index in relation to hormone receptor positive versus hormone receptor negative breast cancer incidence and mortality

Principal Investigator
Name
Omar Abdel-Rahman
Degrees
MD
Institution
Avicenna Oncology center
Position Title
Consultant and scientific director
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-432
Initial CDAS Request Approval
Dec 28, 2018
Title
Pre-diagnostic body mass index in relation to hormone receptor positive versus hormone receptor negative breast cancer incidence and mortality
Summary
Numerous studies have suggested a higher risk of breast cancer among patients with higher pre-diagnostic body mass index (BMI). However, little studies paid attention to the differential impact of BMI on hormone receptor positive versus hormone receptor negative breast cancer. Moreover, few studies evaluated the impact of BMI trajectory on breast cancer risk.
Aims

1. To evaluate the impact of pre-diagnostic BMI and BMI trajectory on breast cancer risk stratified by hormone receptor status

Collaborators

1. Dr. Omar Abdel-Rahman
1. Dr. Winson Cheung
2. Dr. Patricia Tang

Related Publications